ALTO 100
Alternative Names: ALTO-100Latest Information Update: 20 Aug 2024
At a glance
- Originator Alto Neuroscience
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Brain derived neurotrophic factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bipolar depression; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 13 Aug 2024 Alto Neuroscience completed a successful Type C meeting with the US FDA provided feedback regarding the phase IIb study
- 25 Jul 2024 Phase-II clinical trials in Bipolar depression (PO)
- 16 Jul 2024 Alto Neuroscience completes enrollment in a phase IIb trial for Major depressive disorder in USA (PO, Tablet) (NCT05712187)